Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PRIVIGEN Granted Orphan-Drug Designation
Details : CSL Behring advances Ig clinical trial program to address need in treating serious autoimmune disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable